The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community

Pre-eclampsia is a major cause of poor outcome in pregnancy: the category “hypertensive diseases of pregnancy” remains a leading cause of direct maternal deaths in the United Kingdom1; pre-eclamptic conditions represent one in three cases of severe obstetric morbidity2; hypertension and/or proteinuria is the leading single identifiable risk factor in pregnancy associated with stillbirth (one in five stillbirths in otherwise viable babies)3; and pre-eclampsia is strongly associated with fetal growth restriction, low birth weight, preterm delivery, respiratory distress syndrome, and admission to neonatal intensive care.4 In 46% of maternal deaths1 and 65% of fetal deaths5 due to pre-eclampsia reported through the Confidential Enquiries into Maternal Deaths and the Confidential Enquiry into Stillbirths and Deaths in Infancy, different management would reasonably have expected to alter the outcome. There was a failure to identify and act on known risk factors at booking and to recognise and respond to signs and symptoms from 20 weeks' gestation.6 No guidelines exist for the screening and early detection of pre-eclampsia in the community, and there is no uniformity in referral thresholds and assessment procedures. We developed the pre-eclampsia community guideline (PRECOG) under the auspices of the charity Action on Pre-eclampsia, following the National Institute for Clinical Excellence's recommendations for the development of guidelines.7 Our guideline is supported by the Royal College of Obstetricians and Gynaecologists, the Royal College of Midwives, the Royal College of General Practitioners, and the National Childbirth Trust. Box 1 lists the definitions used in the guideline; pre-eclampsia is defined as new hypertension and proteinuria (see bmj.com for definition of levels of evidence). The pre-eclampsia community guideline provides an evidence based risk assessment, with criteria for early referral for specialist input, a two tiered schedule for monitoring women in the community after …

[1]  L. Hirsch Competing interests: none declared. , 2006 .

[2]  Kirsten Duckitt,et al.  Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies , 2005, BMJ : British Medical Journal.

[3]  A. Shennan,et al.  A prospective comparison of total protein/creatinine ratio versus 24-hour urine protein in women with suspected preeclampsia. , 2004, American journal of obstetrics and gynecology.

[4]  B. Mercer,et al.  A prospective comparison of total protein/creatinine ratio versus 24-hour urine protein in women with suspected preeclampsia. , 2003, American journal of obstetrics and gynecology.

[5]  D. Altman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[6]  S. Matsubara,et al.  Recurrence Risk of Preterm Birth due to Preeclampsia , 2002, Gynecologic and Obstetric Investigation.

[7]  M. Mugford,et al.  WHO systematic review of randomised controlled trials of routine antenatal care , 2001, The Lancet.

[8]  S. Bewley,et al.  Incidence and predictors of severe obstetric morbidity: case-control study. , 2001, BMJ : British Medical Journal.

[9]  B. Sibai,et al.  Mild gestational hypertension remote from term: progression and outcome. , 2001, American journal of obstetrics and gynecology.

[10]  J. Henderson,et al.  An Economic Evaluation Comparing Two Schedules of Antenatal Visits , 2000, Journal of health services research & policy.

[11]  M. Morgan,et al.  Can antenatal clinical and biochemical markers predict the development of severe preeclampsia? , 2000, American journal of obstetrics and gynecology.

[12]  R. North,et al.  Evaluation of a definition of pre‐eclampsia , 1999, British journal of obstetrics and gynaecology.

[13]  J. N. Martin,et al.  Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. , 1999, American journal of obstetrics and gynecology.

[14]  G. Saade,et al.  Risk factors for abruptio placentae and eclampsia: analysis of 445 consecutively managed women with severe preeclampsia and eclampsia. , 1999, American journal of obstetrics and gynecology.

[15]  I. Venkataraman,et al.  Hypertension in pregnancy. Outcomes, proteinuric vs. nonproteinuric. , 1997, The Journal of reproductive medicine.

[16]  R. Frankowski,et al.  Case-control study of the risk factors for eclampsia. , 1995, American journal of epidemiology.

[17]  C. Redman,et al.  Eclampsia in the United Kingdom , 1994, BMJ.

[18]  Philip K. Bock Ethical Approval Not Required , 1994 .

[19]  B. Sibai,et al.  Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. , 1994, American journal of obstetrics and gynecology.

[20]  T. Nolan,et al.  Severe Preeclampsia in Preterm Pregnancy Between 26 and 32 Weeks' Gestation , 1992, American journal of perinatology.

[21]  D. Wlody,et al.  Hypertension in pregnancy. , 1992, The New England journal of medicine.

[22]  F. Cunningham,et al.  Natural history of chronic proteinuria complicating pregnancy. , 1992, American journal of obstetrics and gynecology.

[23]  A. Caruso,et al.  Proteinuria and outcome of 444 pregnancies complicated by hypertension. , 1990, American journal of obstetrics and gynecology.

[24]  T. Forrester,et al.  Hypertensive diseases of pregnancy. , 1985, The West Indian medical journal.